Scilex Holding's 15min chart triggers KDJ Golden Cross, Bullish Marubozu Signal.

Scilex Holding's 15-minute chart has recently undergone a significant development, as it has triggered a KDJ Golden Cross and Bullish Marubozu pattern on August 20, 2025, at 14:00. This technical indicator suggests that the momentum of the stock price is shifting towards an upward trajectory, with a potential for further growth. As buyers maintain control of the market, it is likely that bullish momentum will continue to prevail.

Scilex Holding Company (SCLX) experienced a significant surge in its stock price, with shares climbing over 17% on August 13, 2025, following a key regulatory milestone. The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form S-4 filed in connection with the proposed merger between Denali Capital Acquisition Corp. (OTCB: DNQAF) and Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex. The merger is expected to enhance Scilex's market presence and provide an expanded platform in pain management and specialty pharmaceuticals [1].

The merger, if approved by shareholders on September 3, 2025, will result in the formation of Semnur Pharmaceuticals, Inc. Post-closing, the combined company plans to list its common stock and warrants on the Nasdaq Stock Market, although approval for the listing is still pending [1].

Technical indicators also suggest a potential upward trajectory for Scilex's stock. On August 20, 2025, at 14:00, Scilex's 15-minute chart triggered a KDJ Golden Cross and Bullish Marubozu pattern, indicating a shift in momentum towards an upward trajectory. This pattern, often seen in technical analysis, suggests that buyers are maintaining control of the market, potentially leading to further growth [2].

Market performance has been volatile for Scilex over recent years. As of August 13, 2025, the company’s trailing returns were:
- YTD: +40.02%
- 1-Year: -54.47%
- 3-Year: -94.22%
- 5-Year: -93.94%

These returns highlight Scilex's challenging trajectory despite the recent rally. By comparison, the S&P 500 has posted gains of 9.60% YTD, 18.62% over the past year, and 91.09% over five years [1].

The September 3 shareholder vote will be a pivotal step toward determining whether the merger moves forward. Market participants remain watchful, awaiting the outcome of the vote and the potential Nasdaq listing approval. The strategic outlook for Scilex is promising, with the merger positioned to bolster Semnur's market presence and provide an expanded platform in pain management and specialty pharmaceuticals [1].

References:
[1] https://coincentral.com/scilex-holding-company-sclx-stock-surges-over-17-as-sec-clears-path-for-denali-semnur-merger-vote-in-september/
[2] [Provided source materials]